Approvals & regulatory · first seen 2h ago, updated 2h ago
FDA Approves New Option for Previously Treated Bile Duct Cancer
(MedPage Today) -- The FDA approved the oral fibroblast growth factor receptor 2 (FGFR2) inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangements, the agency a…
Summary from MedPage Today.